Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.

摘要: While current trials of anticancer agents serve to provide a population-based validation therapeutic activity, clinical success is typically restricted tumors select molecular subtype. Recent insights have yielded growing catalogue germline and tumor-based aberrations that can predetermine whether patient will achieve benefit from drug or not. Thus, in order realize the true potential agents, we need define contexts under which they prove both efficacious safe. In this article, an overview such determinants introduce concept ‘cancer profiling’ – process science defining optimal therapy for given through generation analysis system-wide information.